Laparoendoscopic Rendez Vous Versus Standard Two Stage Approach for the Management of Cholelithiasis/Choledocholithiasis
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to assess whether combined intraoperative ERCP and CBD clearance with laparo-endoscopic rendez-vous during laparoscopic cholecystectomy (one stage approach) is or not superior to the standard practice of preoperative ERCP, sphincterotomy and CBD clearance followed by laparoscopic cholecystectomy (two stage approach) in patients with combined cholelithiasis and choledocholithiasis.
| Condition | Intervention |
|---|---|
|
Choledocholithiasis Cholelithiasis |
Procedure: Laparoendoscopic Rendez vous Procedure: preoperative ERCP and CBD clearance |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Laparoendoscopic Rendez Vous (Intraoperative ERCP) vs Two Stage Approach (Preoperative ERCP Followed by Laparoscopic Cholecystectomy) for the Management of Cholelithiasis/Choledocholithiasis |
- postoperative hospital stay [ Time Frame: from onset of intervention to discharge ] [ Designated as safety issue: No ]
- success rate of CBD clearance [ Time Frame: during ERCP ] [ Designated as safety issue: Yes ]
- failure rate of selective CBD cannulation [ Time Frame: during ERCP ] [ Designated as safety issue: Yes ]
- incidence of multiple endoscopic procedures [ Time Frame: within 30 days ] [ Designated as safety issue: Yes ]
- incidence of hyperamylasemia [ Time Frame: within 48 hours post-ERCP ] [ Designated as safety issue: Yes ]
- incidence of severe pancreatitis (APACHE II score >6) [ Time Frame: within 48 hours post-ERCP ] [ Designated as safety issue: Yes ]
- total hospital stay [ Time Frame: from admission to discharge ] [ Designated as safety issue: No ]
- complications other but pancreatitis [ Time Frame: within 30 days ] [ Designated as safety issue: Yes ]
- death [ Time Frame: within 30 days ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 300 |
| Study Start Date: | September 2006 |
| Estimated Study Completion Date: | December 2010 |
| Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Laparoendoscopic Rendez vous (one stage management of cholelithiasis/choledocholithiasis)
|
Procedure: Laparoendoscopic Rendez vous
intraoperative ERCP for CBD clearance during laparoscopic cholecystectomy
|
|
Active Comparator: 2
preoperative ERCP and CBD clearance followed by lap cholecystectomy (two stage management of cholelithiasis/choledocholithiasis)
|
Procedure: preoperative ERCP and CBD clearance
ERCP and CBD clearance followed by laparoscopic cholecystectomy
|
Detailed Description:
The ideal management of concomitant cholelithiasis and choledocholithiasis is not known yet. There are several options, including one-stage or two-stage approaches. The most commonly used practice is the two-stage management which consists of preoperative ERCP, sphincterotomy and CBD clearance followed by laparoscopic cholecystectomy. However, with this approach, a number of patients will be submitted to an unnecessary ERCP while some others will develop complications, mainly pancreatitis due to inadvertent pancreatic duct cannulation. Laparo-endoscopic rendez-vous methods have been described in order to obtain selective CBD cannulation and omit the risk of post-ERCP pancreatitis. In this procedure, during laparoscopic cholecystectomy, a wire is inserted through the cystic duct into the common bile duct, advanced into the duodenum where is found endoscopically, gripped with a snare and retrieved through the mouth. The a sphincterotome is inserted over the wire and elective CBD cannulation is obtained to be followed by sphincterotomy and CBD clearance intraoperatively. The method has been described by several authors in small to moderate case series, its safety has been proven and it appears that reduces both the length of hospital stay and the incidence of post-ERCP pancreatitis.However, it has not been popularized and has never been tested over the standard two-stage management. In our hospital, the standard approach for cholelithiasis and choledocholithiasis has been, as well, the two-stage (preop ERCP and sphincterotomy followed by laparoscopic cholecystectomy)approach. We initially assessed the feasibility and safety of the laparo-endoscopic rendez vous with a pilot study and now we intend to compare the two methods in a prospective randomized trial.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients must be able to give informed consent preoperatively
- ASA I-III
- patients at high risk to have CBD stones (jaundice, cholangitis, grossly deranged LFTs, CBD stones found on US or MRCP)
Exclusion Criteria:
- patients not fit for surgery (ASA IV)
- previous ERCP and sphincterotomy
- previous upper abdominal surgery
- pregnancy at time of surgery
Contacts and Locations| Contact: George Tzovaras, MD | +30 2410 682730 | gtzovaras@hotmail.com |
| Contact: Ioannis Baloyiannis, MD | +30 2410 682728 | balioan@hotmail.com |
| Greece | |
| University Hospital of Larissa | Recruiting |
| Larissa, Thessaly, Greece, 413 35 | |
| Contact: George Tzovaras, MD +30 2410 682730 gtzovaras@hotmail.com | |
| Principal Investigator: Ioannis Baloyiannis, MD | |
| Sub-Investigator: Spyros Potamianos, MD | |
| Sub-Investigator: George Paroutoglou, MD | |
| Sub-Investigator: Georgia Stamatiou, MD | |
| Study Chair: | Constantine Hatzitheofilou, MD | University of Thessaly, School of Medicine |
| Study Director: | George Tzovaras, MD | University of Thessaly, School of Medicine |
| Principal Investigator: | Ioannis Baloyiannis, MD | University Hospital of Larissa |
More Information
No publications provided by University of Thessaly
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | George Tzovaras, MD, University of Thessaly, School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00416234 History of Changes |
| Other Study ID Numbers: | Larissa CBD stones trial |
| Study First Received: | December 26, 2006 |
| Last Updated: | January 13, 2010 |
| Health Authority: | Greece: Ministry of Health and Welfare |
Additional relevant MeSH terms:
|
Common Bile Duct Diseases Bile Duct Diseases Cholelithiasis Cholecystolithiasis Gallstones Choledocholithiasis |
Biliary Tract Diseases Digestive System Diseases Gallbladder Diseases Calculi Pathological Conditions, Anatomical |
ClinicalTrials.gov processed this record on May 22, 2013